Author contributions
Porras Bueno Cristian Orlando: Wrote and reviewed the manuscript and was
involved in data acquisition and analysis.
Saldarriaga Giraldo Clara Ines:
Conceived and designed the study
and reviewed the manuscript.
Roncancio Villamil Gustavo Eduardo: Conceived and designed the study and
reviewed the manuscript.
Álvarez Barreneche María Fernanda: Conceived and designed the study and
reviewed the manuscript.
References
1. Miloslavsky E,
Unizony S. The Heart in Vasculitis. Rheum Dis Clin North Am
[Internet]. 2014;40(1):11–26. Available from:
http://dx.doi.org/10.1016/j.rdc.2013.10.006
2. Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne
DR, et al. ANCA-associated vasculitis. Nat Rev Dis Prim [Internet].
2020;6(1):71. Available from:
http://dx.doi.org/10.1038/s41572-020-0204-y
3. Bond M, Fagni F, Moretti M, Bello F, Egan A, Vaglio A, et
al. At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into
Cardiac and Vascular Involvement. Curr Rheumatol Rep [Internet].
2022;24(11):337–51. Available from:
https://doi.org/10.1007/s11926-022-01087-1
4. Massussi M, Scotti A, Lip GYH, Proietti R. Left ventricular
thrombosis : new perspectives on an old problem. Eur Heart J.
2021;7:158–67.
5. Franks TJ, Koss MN. Pulmonary capillaritis. Curr Opin Pulm
Med. 2000;6:430–5.
6. Shuai ZW, Lv YF, Zhang MM, Hu ZY. Clinical analysis of
patients with myeloperoxidase antineutrophil cytoplasmic
antibody-associated vasculitis. Genet Mol Res. 2015;14(2):5296–303.
7. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote
F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory
findings in eighty-five patients. Arthritis Care Res (Hoboken).
1999;42(3):421–30.
8. Silveira LH. Cardiovascular Manifestations of Systemic
Vasculitides. Curr Rheumatol Rep. 2020;22:72.
9. Savvoulidis P, Butler J, Kalogeropoulos A. Cardiomyopathy
and Heart Failure in Patients with Human Immunodeficiency Virus
Infection. Can J Cardiol [Internet]. 2018;35(3):299–309. Available
from: https://doi.org/10.1016/j.cjca.2018.10.009
10. Brinkman K, Hofstede HJM, Burger DM, Smeitink JAM, Koopmans
PP. Adverse effects of reverse transcriptase inhibitors : mitochondrial
toxicity as common pathway. AIDS. 1998;12:1735–44.
11. Lewis W, Copeland WC, Day BJ. Mitochondrial DNA depletion,
oxidative stress, and mutation: Mechanisms of dysfunction from
nucleoside reverse transcriptase inhibitors. Lab Investig.
2001;81(6):777–90.
12. Lewis W, Grupp IL, Günter G, Hoit B, Morris R, Samarel AM,
et al. Cardiac Dysfunction Occurs in the HIV-1 Transgenic Mouse Treated
with Zidovudine. Lab Investig. 2000;80(2):187–97.
13. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie
AM, Park Y, et al. Hepatic failure and lactic acidosis due to
fialuridine (FIAU), an investigational nucleoside analogue for chronic
hepatitis B. N Engl J Med. 1995;333(17):1099–105.
14. Comereski CR, Kelly WA, Davidson TJ, Warner WA, Hopper LD,
Oleson FB. Acute Cardiotoxicity of Nucleoside Analogs FddA and FddI in
Rats. Fundam Appl Toxicol Off J Soc Toxicol. 1993;20:360–4.
15. Alvi RM, Neilan AM, Tariq N, Awadalla M, Afshar M, Banerji
D, et al. Protease Inhibitors and Cardiovascular Outcomes in Patients
With HIV and Heart Failure. JACC. 2018;72(5):518–30.
16. Liu C, Ferrari VA, Han Y. Cardiovascular Magnetic Resonance
Imaging and Heart Failure. Curr Cardiol Rep. 2021;23(4):35.
17. Karamitsos TD, Arvanitaki A, Karvounis H, Neubauer S,
Ferreira V. Myocardial Tissue Characterization and Fibrosis by Imaging.
JACC Cardiovasc Imaging. 2019;13(5):1221–34.
18. Navas-nacher EL, Colangelo L, Beam C. Risk Factors for
Coronary Heart Disease in Men 18 to 39 Years of Age. Ann Intern Med.
2001;134:433–9.
19. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G,
et al. 2021 American College of Rheumatology / Vasculitis Foundation
Guideline for the Management of Antineutrophil Cytoplasmic
Antibody–Associated Vasculitis. Arthritis Care Res (Hoboken).
2021;73(8):1088–105.
20. Task A, Members F, Mcdonagh TA, United C, Gardner RS, Force
T, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute
and chronic heart failure Developed by the Task Force for the diagnosis
and treatment of acute and chronic heart failure of the European Society
of Cardiology (ESC). With the special contribut. Eur Heart J.
2021;42:3599–726.
21. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byunt JJ,
Colvin MM, et al. 2022 AHA / ACC / HFSA Guideline for the Management of
Heart Failure : A Report of the American College of Cardiology /
American Heart Association Joint Committee on Clinical Practice
Guidelines. Circulation. 2022;145:e895–1032.